Biologics for dengue prevention: up-to-date

References

• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013 Apr 25;496(7446):504–507.
   PubMed Web of Science ®Google Scholar
• Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21(st) century. Trop Med Health. 2011 Dec;39(4 Suppl):3–11.
   PubMedGoogle Scholar
• Leder K, Mutsch M, Schlagenhauf P, et al. Seroepidemiology of dengue in travellers: a paired sera analysis. Travel Med Infect Dis. 2013 Jul-Aug;11(4):210–213.
   PubMed Web of Science ®Google Scholar
• Ratnam I, Leder K, Black J, et al. Dengue fever and international travel. J Travel Med. 2013 Nov-Dec;20(6):384–393.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Farrar JJ, Nguyen VV, et al. Dengue. N Engl J Med. [2012 Apr 12];366(15):1423–1432.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Gubler DJ, Izquierdo A, et al. Dengue infection. Nat Rev Dis Primers. 2016 Aug 18;2:16055.
   PubMed Web of Science ®Google Scholar
• Muller DA, Depelsenaire AC, Young PR. Clinical and laboratory diagnosis of dengue virus infection. J Infect Dis. 2017 Mar 1;215(suppl_2):S89–S95.
   PubMedGoogle Scholar
• Fukusumi M, Arashiro T, Arima Y, et al. Dengue sentinel traveler surveillance: monthly and yearly notification trends among japanese travelers, 2006-2014. PLoS Negl Trop Dis. 2016 Aug;10(8):e0004924.
   PubMed Web of Science ®Google Scholar
• Rajapakse S, de Silva NL, Weeratunga P, et al. Prophylactic and therapeutic interventions for bleeding in dengue: a systematic review. Trans R Soc Trop Med Hyg. [2017 Oct 1];111(10):433–439.
   PubMed Web of Science ®Google Scholar
• Wong JG, Thein TL, Leo YS, et al. Identifying adult dengue patients at low risk for clinically significant bleeding. PLoS One. 2016;11(2):e0148579.
   PubMed Web of Science ®Google Scholar
• Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis. 1997 Aug;176(2):313–321.
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, et al. Natural history of plasma leakage in dengue hemorrhagic fever: a serial ultrasonographic study. Pediatr Infect Dis J. 2007Apr;26(4):283–290. discussion 291-2
   PubMed Web of Science ®Google Scholar
• Anderson KB, Gibbons RV, Cummings DA, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. [2014 Feb 1];209(3):360–368.
   PubMed Web of Science ®Google Scholar
• Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7(8):e2357.
   PubMed Web of Science ®Google Scholar
• Schmidt AC. Response to dengue fever–the good, the bad, and the ugly? N Engl J Med. 2010 Jul 29;363(5):484–487.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis. [2002 May 1];185(9):1213–1221.
   PubMed Web of Science ®Google Scholar
• Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, et al. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A. [2003 Nov 25];100(24):14333–14338.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Popper S, Dolocek C, et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis. [2007 Apr 15];195(8):1097–1107.
   PubMed Web of Science ®Google Scholar
• Lok SM. The interplay of dengue virus morphological diversity and human antibodies. Trends Microbiol. 2016 Apr;24(4):284–293.
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Ludert JE. The Dual Role of the Antibody Response Against the Flavivirus Non-structural Protein 1 (NS1) in Protection and Immuno-Pathogenesis. Front Immunol. 2019;10:1651.
   PubMed Web of Science ®Google Scholar
• Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis. 1994 Sep;19(3):500–512.
   PubMed Web of Science ®Google Scholar
• Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis. 1979 Oct;140(4):527–533. •• A pivitol study which demonstrated that naturally aquired human anti-DENV antibodies can enhance DENV replication in non-human primates.
   PubMed Web of Science ®Google Scholar
• Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr. 2014 Dec;2(6).
   PubMedGoogle Scholar
• Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011 Aug;11(8):532–543.
   PubMed Web of Science ®Google Scholar
• Kontny U, Kurane I, Ennis FA. Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. J Virol. 1988 Nov;62(11):3928–3933.
   PubMed Web of Science ®Google Scholar
• Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000 Jan;181(1):2–9. •• Study examining the relationship between viral titer, antibody response, and symptom severity in children experiencing acute dengue infections.
   PubMed Web of Science ®Google Scholar
• Kuberski T, Rosen L, Reed D, et al. Clinical and laboratory observations on patients with primary and secondary dengue type 1 infections with hemorrhagic manifestations in Fiji. Am J Trop Med Hyg. 1977 Jul;26(4):775–783.
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017 Nov 17;358(6365): 929–932. •• Analysis of a long-term study of Nicaraguan children exposed to dengue virus that examined the relationship between pre-infection antibody titers and the clinical outcome of infection.
   PubMed Web of Science ®Google Scholar
• Salje H, Cummings DAT, Rodriguez-Barraquer I, et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature. 2018 May;557(7707):719–723.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Dong T, Chau NV, et al. Early T-cell responses to dengue virus epitopes in vietnamese adults with secondary dengue virus infections. J Virol. 2005 May;79(9):5665–5675.
   PubMed Web of Science ®Google Scholar
• Friberg H, Bashyam H, Toyosaki-Maeda T, et al. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci Rep. 2011;(1):51.
   PubMed Web of Science ®Google Scholar
• Ooi EE, Goh KT, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis. 2006 Jun;12(6):887–893.
   PubMed Web of Science ®Google Scholar
• Cardosa J, Ooi MH, Tio PH, et al. Dengue virus serotype 2 from a sylvatic lineage isolated from a patient with dengue hemorrhagic fever. PLoS Negl Trop Dis. 2009;3(4):e423.
   PubMed Web of Science ®Google Scholar
• Vasilakis N, Cardosa J, Hanley KA, et al. Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health. Nat Rev Microbiol. 2011 Jul;9(7):532–541.
   PubMed Web of Science ®Google Scholar
• Weaver SC, Vasilakis N. Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease. Infect Genet Evol. 2009 Jul;9(4):523–540.
   PubMed Web of Science ®Google Scholar
• Cassetti MC, Durbin A, Harris E, et al. Report of an NIAID workshop on dengue animal models. Vaccine. [2010 Jun 11];28(26):4229–4234.
   PubMed Web of Science ®Google Scholar
• Zompi S, Harris E. Animal models of dengue virus infection. Viruses. 2012 Jan;4(1):62–82.
   PubMed Web of Science ®Google Scholar
• Whitehorn J, Van VC, Simmons CP. Dengue human infection models supporting drug development. J Infect Dis. 2014 Jun 15;209(Suppl 2):66–70.
   PubMedGoogle Scholar
• Thomas SJ. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum Vaccin Immunother. 2013 Jul;9(7):1587–1590.
   PubMed Web of Science ®Google Scholar
• Larsen CP, Whitehead SS, Durbin AP. Dengue human infection models to advance dengue vaccine development. Vaccine. 2015 Dec 10;33(50):7075–7082.
   PubMed Web of Science ®Google Scholar
• Endy TP. Dengue human infection model performance parameters. J Infect Dis. 2014 Jun 15;209(Suppl 2):S56–60.
   PubMedGoogle Scholar
• Hombach J. Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev Panam Salud Publica. 2007 Apr;21(4):254–260.
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue Viruses. Viral Immunol. 2008 Jun;21(2):123–132.
   PubMed Web of Science ®Google Scholar
• Russell PK, Nisalak A, Sukhavachana P, et al. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol. 1967 Aug;99(2):285–290.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Nisalak A, Anderson KB, et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg. 2009 Nov;81(5):825–833.
   PubMed Web of Science ®Google Scholar
• Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, et al. Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. BMC Infect Dis. 2012;12:233.
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Thomas SJ, et al. Dengue vaccine: global development update. Asian Pac J Allergy Immunol. 2020 Sep;38(3):178–185.
   Web of Science ®Google Scholar
• Villar L, Dayan GH, Arredondo-Garcia JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. [2015 Jan 8];372(2):113–123.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. [2014 Oct 11];384(9951):1358–1365.
   PubMed Web of Science ®Google Scholar
• Coudeville L, Baurin N, Shepard DS. The potential impact of dengue vaccination with, and without, pre-vaccination screening. Vaccine. 2020 Feb 5;38(6):1363–1369.
   PubMed Web of Science ®Google Scholar
• Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines. 2016;15(4):497–508.
   PubMed Web of Science ®Google Scholar
• Tricou V, Saez-Llorens X, Yu D, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet. [2020 May 2];395(10234):1434–1443.
   PubMed Web of Science ®Google Scholar
• Biswal S, Reynales H, Saez-Llorens X, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. [2019 Nov 21];381(21):2009–2019.
   PubMed Web of Science ®Google Scholar
• Biswal S, Borja-Tabora C, Martinez Vargas L, et al. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet. [2020 May 2];395(10234):1423–1433.
   PubMed Web of Science ®Google Scholar
• Takeda’s. QDENGA (dengue tetravalent vaccine [live, attenuated]) approved in indonesia for use regardless of prior Dengue Exposure; cited 2022 Aug 22:[ Available from: https://www.takeda.com/newsroom/newsreleases/2022/takedas-qdenga-dengue-tetravalent-vaccine-live-attenuated-approved-in-indonesia-for-use-regardless-of-prior-dengue-exposure/
   Google Scholar
• Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine? Expert Rev Vaccines. 2016;15(4):509–517.
   PubMed Web of Science ®Google Scholar
• Russell KL, Rupp RE, Morales-Ramirez JO, et al. A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naive and flavivirus-experienced healthy adults. Hum Vaccin Immunother. [2022 Nov 30];18(5):2046960.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. [2012 Nov 3];380(9853):1559–1567.
   PubMed Web of Science ®Google Scholar
• Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr;2(2):60–67.
   PubMed Web of Science ®Google Scholar
• Morrison D, Legg TJ, Billings CW, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. [2010 Feb 1];201(3):370–377.
   PubMed Web of Science ®Google Scholar
• Poo J, Galan F, Forrat R, et al. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in mexico city: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. 2011 Jan;30(1):9–17.
   PubMed Web of Science ®Google Scholar
• Capeding RZ, Luna IA, Bomasang E, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. [2011 May 17];29(22):3863–3872.
   PubMed Web of Science ®Google Scholar
• Qiao M, Shaw D, Forrat R, et al. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg. 2011 Oct;85(4):724–731.
   PubMed Web of Science ®Google Scholar
• Lanata CF, Andrade T, Gil AI, et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura. Peru. Vaccine. 2012 Sep 7;30(41):5935–5941.
   PubMed Web of Science ®Google Scholar
• Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012 Sep;8(9):1259–1271.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Garbes P, Noriega F, et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg. 2013 Dec;89(6):1058–1065.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Thakur M, Boaz M, et al. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine. [2013 Oct 17];31(44):5047–5054.
   PubMed Web of Science ®Google Scholar
• Villar LA, Rivera-Medina DM, Arredondo-Garcia JL, et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J. 2013 Oct;32(10):1102–1109.
   PubMed Web of Science ®Google Scholar
• Dubey AP, Agarkhedkar S, Chhatwal J, et al. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: a randomized, observer-blind, placebo-controlled phase II trial. Hum Vaccin Immunother. 2016;12(2):512–518.
   PubMed Web of Science ®Google Scholar
• Kirstein J, Douglas W, Thakur M, et al. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults. BMC Infect Dis. [2018 Sep 21];18(1):475.
   PubMedGoogle Scholar
• Cortes M, Lopez P, Marquez V, et al. Safety follow-up of a dengue vaccine when administered concomitantly with a yellow fever vaccine in healthy toddlers in colombia. Pediatr Infect Dis J. 2018 Nov;37(11):1190–1191.
   PubMed Web of Science ®Google Scholar
• Glass A, Polhemus M, Wang D, et al. The effects of japanese encephalitis vaccine and accelerated dosing scheduling on the immunogenicity of the chimeric yellow fever derived tetravalent dengue vaccine (CYD-TDV): a phase II, randomized, open-label, single center trial in adults aged 18 to 45 years in the United States. J Infect Dis. 2020 Mar 16;221(7):1057–1069.
   Web of Science ®Google Scholar
• Torresi J, Heron LG, Qiao M, et al. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. Vaccine. [2015 Sep 22];33(39):5127–5134.
   PubMed Web of Science ®Google Scholar
• Hss AS, Koh MT, Tan KK, et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine. [2013 Dec 2];31(49):5814–5821.
   PubMed Web of Science ®Google Scholar
• Melo FIR, Morales JJR, De Los Santos AHM, et al. Immunogenicity and safety of a booster injection of DTap-IPV//hib (pentaxim) administered concomitantly with tetravalent dengue vaccine in healthy toddlers 15-18 months of age in mexico: a randomized trial. Pediatr Infect Dis J. 2017 Jun;36(6):602–608.
   PubMed Web of Science ®Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015 Sep 24;373(13):1195–1206.
   PubMed Web of Science ®Google Scholar
• Schmidt AC, Lin L, Martinez LJ, et al. Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States. Am J Trop Med Hyg. 2017 Jun;96(6):1325–1337.
   PubMed Web of Science ®Google Scholar
• Friberg H, Martinez LJ, Lin L, et al. Cell-Mediated immunity generated in response to a purified inactivated vaccine for dengue virus type 1. mSphere. 2020 Jan 22;5(1):e00671–19.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Eckels KH, Carletti I, et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg. 2013 Jan;88(1):73–88.
   PubMed Web of Science ®Google Scholar
• Lin L, Koren MA, Paolino KM, et al. Immunogenicity of a live-attenuated dengue vaccine using a heterologous prime-boost strategy in a phase 1 randomized clinical trial. J Infect Dis. [2021 May 28];223(10):1707–1716.
   PubMed Web of Science ®Google Scholar
• Manoff SB, Sausser M, Falk Russell A, et al. Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naive adults. Hum Vaccin Immunother. 2019;15(9):2195–2204.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Pierce KK, Kirkpatrick BD, et al. Immunogenicity and safety of a tetravalent recombinant subunit dengue vaccine in adults previously vaccinated with a live attenuated tetravalent dengue vaccine: results of a phase-I randomized clinical trial. Am J Trop Med Hyg. 2020 Aug;103(2):855–863.
   PubMed Web of Science ®Google Scholar
• Jiang J, Ramos SJ, Bangalore P, et al. Multivalent DNA vaccines as a strategy to combat multiple concurrent epidemics: mosquito-borne and hemorrhagic fever viruses. Viruses. 2021 Feb 27;13(3):382.
   Web of Science ®Google Scholar
• Sankaradoss A, Jagtap S, Nazir J, et al. Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences. Mol Ther. [2022 May 4];30(5):2058–2077.
   PubMed Web of Science ®Google Scholar
• Wollner CJ, Richner M, Hassert MA, et al. A Dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses. J Virol. 2021 May 24;95(12):e02482–20.
   PubMed Web of Science ®Google Scholar
• Roth C, Cantaert T, Colas C, et al. A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice. Front Immunol. 2019;10:1424.
   PubMed Web of Science ®Google Scholar
• De Clercq E, Li G. Approved antiviral drugs over the past 50 Years. Clin Microbiol Rev. 2016 Jul;29(3):695–747.
   PubMed Web of Science ®Google Scholar
• Blair W, Cox C. Current landscape of antiviral drug discovery. F1000Res. 2016;5(F1000 Faculty Rev):202.
   PubMedGoogle Scholar
• Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood). 2006 Mar-Apr;25(2):420–428.
   PubMed Web of Science ®Google Scholar
• Low JG, Gatsinga R, Vasudevan SG, et al. Dengue antiviral development: a continuing journey. Adv Exp Med Biol. 2018;1062:319–332.
   PubMed Web of Science ®Google Scholar
• Low JG, Ooi EE, Vasudevan SG. Current status of dengue therapeutics research and development. J Infect Dis. 2017 Mar 1;215(suppl_2):S96–S102.
   PubMedGoogle Scholar
• Kaptein SJF, Goethals O, Kiemel D, et al. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. Nature. 2021 Oct;598(7881):504–509.
   PubMed Web of Science ®Google Scholar
• Wang C, Yang SNY, Smith K, et al. Nuclear import inhibitor N-(4-hydroxyphenyl) retinamide targets Zika virus (ZIKV) nonstructural protein 5 to inhibit ZIKV infection. Biochem Biophys Res Commun. [2017 Dec 2];493(4):1555–1559.
   PubMed Web of Science ®Google Scholar
• Pitts JD, Li PC, de Wispelaere M, et al. Antiviral activity of N-(4-hydroxyphenyl) retinamide (4-HPR) against Zika virus. Antiviral Res. 2017;147:124–130.
   PubMed Web of Science ®Google Scholar
• Carocci M, Hinshaw SM, Rodgers MA, et al. The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication. Antimicrob Agents Chemother. 2015 Jan;59(1):85–95.
   PubMed Web of Science ®Google Scholar
• Good SS, Shannon A, Lin K, et al. Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses. Antimicrob Agents Chemother. [2021 Oct 18];65(11):e0098821.
   PubMed Web of Science ®Google Scholar
• Moquin SA, Simon O, Karuna R, et al. NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Sci Transl Med. 2021 Feb 3;13(579):eabb2181.
   PubMed Web of Science ®Google Scholar
• Low JG, Sung C, Wijaya L, et al. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis. 2014 Aug;14(8):706–715.
   PubMed Web of Science ®Google Scholar
• Rathore AP, Paradkar PN, Watanabe S, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res. 2011 Dec;92(3):453–460.
   PubMed Web of Science ®Google Scholar
• Schul W, Liu W, Xu HY, et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis. 2007 Mar 1 195(5):665–674.
   PubMed Web of Science ®Google Scholar
• Smith DB, Martin JA, Klumpp K, et al. Design, synthesis, and antiviral properties of 4’-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg Med Chem Lett. 2007 May 1;17(9):2570–2576.
   PubMed Web of Science ®Google Scholar
• Nguyen NM, Tran CNB, Phung LK, et al. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis. 2013 May 1;207(9):665–674.
   Web of Science ®Google Scholar
• Warfield KL, Plummer EM, Sayce AC, et al. Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4. Antiviral Res. 2016 May;129:93–98.
   PubMed Web of Science ®Google Scholar
• Crump A, Omura SI. ‘wonder drug’ from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(2):13–28.
   PubMed Web of Science ®Google Scholar
• Fraser JE, Rawlinson SM, Wang C, et al. Investigating dengue virus nonstructural protein 5 (NS5) nuclear import. Methods Mol Biol. 2014;1138:301–328.
   PubMedGoogle Scholar
• Tay MY, Fraser JE, Chan WK, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. 2013 Sep;99(3):301–306.
   PubMed Web of Science ®Google Scholar
• Xu T-L, Han Y, Liu W, et al. Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus. PLoS Negl Trop Dis. 2018 Nov;12(11):e0006934.
   PubMed Web of Science ®Google Scholar
• O’Neill PM, Bray PG, Hawley SR, et al. 4-Aminoquinolines–past, present, and future: a chemical perspective. Pharmacol Ther. 1998 Jan;77(1):29–58.
   PubMed Web of Science ®Google Scholar
• Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: an old drug with new relevance. Cleve Clin J Med. 2018 Jun;85(6):459–467.
   PubMed Web of Science ®Google Scholar
• Townsend KN, Hughson LR, Schlie K, et al. Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. Immunol Rev. 2012 Sep;249(1):176–194.
   PubMedGoogle Scholar
• Farias KJ, Machado PR, da Fonseca BA. Chloroquine inhibits dengue virus type 2 replication in vero cells but not in C6/36 cells. ScientificWorldJournal. 2013;2013:282734.
   PubMedGoogle Scholar
• Farias KJ, Machado PR, de Almeida Junior RF, et al. Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiol Immunol. 2014 Jun;58(6):318–326.
   PubMed Web of Science ®Google Scholar
• Farias KJ, Machado PR, Muniz JA, et al. Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys. Viral Immunol. 2015 Apr;28(3):161–169.
   PubMed Web of Science ®Google Scholar
• Rothman AL. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol. 2010;338:83–98.
   PubMed Web of Science ®Google Scholar
• Lei HY, Yeh TM, Liu HS, et al. Immunopathogenesis of dengue virus infection. J Biomed Sci. 2001 Sep;8(5):377–388.
   PubMed Web of Science ®Google Scholar
• Souza DG, Fagundes CT, Sousa LP, et al. Essential role of platelet-activating factor receptor in the pathogenesis of Dengue virus infection. Proc Natl Acad Sci U S A. [2009 Aug 18];106(33):14138–14143.
   PubMed Web of Science ®Google Scholar
• Ranasinghe P, Ranasinghe P, Abeysekera WP, et al. In vitro erythrocyte membrane stabilization properties of Carica papaya L. leaf extracts. Pharmacognosy Res. 2012 Oct;4(4):196–202.
   PubMedGoogle Scholar
• Rajapakse S, de Silva NL, Weeratunga P, et al. Carica papaya extract in dengue: a systematic review and meta-analysis. BMC Complement Altern Med. [2019 Oct 11];19(1):265.
   PubMed Web of Science ®Google Scholar
• Ben-Eli H, Solomon A. Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends. Curr Opin Allergy Clin Immunol. 2018 Oct;18(5):411–416.
   PubMed Web of Science ®Google Scholar
• Tan JW, Wan Zahidi NF, Kow ASF, et al. Mast cell stabilizing effect of a geranyl acetophenone in dengue virus infection using in vitro model of DENV3-induced RBL-2H3 cells. Biosci Rep. 2019 Jun 28;39(6):BSR20181273.
   Google Scholar
• Morrison J, Rathore APS, Mantri CK, et al. Transcriptional profiling confirms the therapeutic effects of mast cell stabilization in a dengue disease model. J Virol. 2017 Sep 15;91:(18):e00617-17.
   Web of Science ®Google Scholar
• Mitrakul C, Poshyachinda M, Futrakul P, et al. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg. 1977 Sep;26(5 Pt 1):975–984.
   PubMed Web of Science ®Google Scholar
• Chuansumrit A, Tangnararatchakit K, Lektakul Y, et al. The use of recombinant activated factor VII for controlling life-threatening bleeding in dengue shock syndrome. Blood Coagul Fibrinolysis. 2004 Jun;15(4):335–342.
   PubMed Web of Science ®Google Scholar
• Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis. 2005 Nov;16(8):549–555.
   PubMed Web of Science ®Google Scholar
• de Castro Ra, de Castro Ja, Barez MY, et al. Thrombocytopenia associated with dengue hemorrhagic fever responds to intravenous administration of anti-D (Rh(0)-D) immune globulin. Am J Trop Med Hyg. 2007 Apr;76(4):737–742.
   PubMed Web of Science ®Google Scholar
• Yadav SP, Sachdeva A, Gupta D, et al. Control of massive bleeding in dengue hemorrhagic fever with severe thrombocytopenia by use of intravenous anti-D globulin. Pediatr Blood Cancer. 2008 Dec;51(6):812–813.
   PubMed Web of Science ®Google Scholar
• Kharya G, Yadav SP, Katewa S, et al. Management of severe refractory thrombocytopenia in dengue hemorrhagic fever with intravenous anti-D immune globulin. Pediatr Hematol Oncol. 2011 Nov;28(8):727–732.
   PubMed Web of Science ®Google Scholar
• Pannu AK, Bhalla A, Singhal M, et al. safety and efficacy of a single dose of anti-D (WinRho(R)) in severe thrombocytopenia secondary to dengue virus infection. Indian J Crit Care Med. 2017 Feb;21(2):80–84.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Waseem T, Butt NF, et al. Montelukast reduces the risk of dengue shock syndrome in dengue patients. Trop Biomed. [2018 Dec 1];35(4):1115–1122.
   PubMed Web of Science ®Google Scholar
• Budigi Y, Ong EZ, Robinson LN, et al. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein. PLoS Negl Trop Dis. 2018 Feb;12(2):e0006209.
   PubMed Web of Science ®Google Scholar
• Robinson LN, Tharakaraman K, Rowley KJ, et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell. [2015 Jul 30];162(3):493–504.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Endy TP. Current issues in dengue vaccination. Curr Opin Infect Dis. 2013 Oct;26(5):429–434.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Yoon IK. A review of Dengvaxia(R): development to deployment. Hum Vaccin Immunother. 2019;15(10):2295–2314.
   PubMed Web of Science ®Google Scholar
• Guy B, Ooi EE, Ramos-Castaneda J, et al. When can one vaccinate with a live vaccine after wild-type dengue infection? Vaccines (Basel). 2020 Apr 9;8(2):174.
   Web of Science ®Google Scholar
• Vaughn DW, Green S, Kalayanarooj S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis. 1997 Aug;176(2):322–330.
   PubMed Web of Science ®Google Scholar
• Green S, Vaughn DW, Kalayanarooj S, et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis. 1999 Apr;179(4):755–762.
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Harris E. Participants in the summit on dengue immune correlates of P. Immune correlates of protection for dengue: state of the art and research agenda. Vaccine. 2017 Aug 24;35(36):4659–4669.
   PubMed Web of Science ®Google Scholar
• Porter CK, Louis Bourgeois A, Frenck RW, et al. Developing and utilizing controlled human models of infection. Vaccine. [2017 Dec 14];35(49 Pt A):6813–6818.
   PubMed Web of Science ®Google Scholar
• Lyons AG. The human dengue challenge experience at the walter reed army institute of research. J Infect Dis. 2014 Jun 15;209(Suppl 2):S49–55.
   PubMedGoogle Scholar
• Mammen MP, Lyons A, Innis BL, et al. Evaluation of dengue virus strains for human challenge studies. Vaccine. [2014 Mar 14];32(13):1488–1494.
   PubMed Web of Science ®Google Scholar
• Sun W, Eckels KH, Putnak JR, et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis. [2013 Mar 1];207(5):700–708.
   PubMed Web of Science ®Google Scholar
• Endy TP, Wang D, Polhemus ME, et al. A Phase 1, open-label assessment of a dengue Virus-1 live virus human challenge strain. J Infect Dis. [2021 Feb 3];223(2):258–267.
   PubMed Web of Science ®Google Scholar
• Waickman AT, Friberg H, Gromowski GD, et al. Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infections. PLoS Pathog. 2021 Jan;17(1):e1009240.
   PubMed Web of Science ®Google Scholar
• Waickman AT, Lu JQ, Fang H, et al. Evolution of inflammation and immunity in a dengue virus 1 human infection model. Sci Transl Med. [2022 Oct 26];14(668):eabo5019.
   PubMed Web of Science ®Google Scholar